Status:
COMPLETED
Resistance to Antithrombotic Therapy
Lead Sponsor:
Medical University of Vienna
Conditions:
Atherosclerosis
Angioplasty
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Clopidogrel plays a pivotal role in the antithrombotic regimen after percutaneous intervention with stent implantation. However, response to clopidogrel shows a wide interindividual variability and a ...
Eligibility Criteria
Inclusion
- written informed consent
- angioplasty and stenting for peripheral, coronary or carotid artery disease
Exclusion
- known aspirin or clopidogrel intolerance
- therapy with vitamin K antagonists (warfarin, phenprocoumon, acenocoumarol)
- treatment with ticlopidine, dipyridamol or nonsteroidal antiinflammatory drugs
- family or personal history of bleeding disorders
- malignant paraproteinemias
- myeloproliferative disorders
- heparin-induced thrombocytopenia
- severe hepatic failure
- known qualitative defects in thrombocyte function
- major surgical procedure within one week before enrollment
- platelet count \< 100.000 or \> 450.000/µl
- hemoglobin \< 8 g/dl
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00858715
Start Date
May 1 2008
End Date
May 1 2012
Last Update
December 12 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Angiology, Department of Internal Medicine II, Medical University of Vienna
Vienna, Austria, 1090